Key result
Surgery for pediatric obstructive HCM shows ~81% transplant-free survival at 20 years.
Why the study?
Outcomes data on septal reduction surgery via septal myectomy in pediatric patients with obstructive HCM are limited.
Does septal reduction surgery provide good long-term survival and freedom from reintervention in pediatric patients with obstructive hypertrophic cardiomyopathy?
Cohort (n=37)
No
Does septal reduction surgery provide good long-term survival and freedom from reintervention in pediatric patients with obstructive hypertrophic cardiomyopathy?
Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients demonstrates excellent long-term survival, though recurrent outflow tract obstruction requiring reintervention occurs in approximately one-third of patients over 20 years.
May support septal myectomy for durable survival in pediatric obstructive HCM; leaves open optimal timing and reintervention strategies.
Background: Septal reduction therapy via septal myectomy or a modified Konno procedure is the mainstay of therapy for drug-refractory obstructive hypertrophic cardiomyopathy (HCM), although outcomes data on septal myectomy in pediatric patients are limited.We evaluated long-term outcomes following surgery for obstructive HCM in a pediatric cohort. Methods:We retrospectively reviewed patients age 18 years with obstructive HCM who underwent a left and/or right ventricular septal myectomy at our institution between 1992 and 2022.Primary endpoints were transplantation-free survival, freedom from HCM-related death, and cumulative probability of HCM-related reintervention.We further evaluated outcomes in patients with and without Noonan syndrome or other RASopathies.Results: Thirty-seven patients (median age, 7.4 years; interquartile range [IQR], 3.4-12.9years) underwent transaortic septal myectomy.A combined modified Konno procedure was performed in 5 patients (13.9%).Sixteen patients (43.2%) had a RASopathy.A concomitant right ventricular outflow tract resection was performed in 9 patients (24.3%).There was 1 (2.7%) in-hospital death and 4 late deaths at a median follow-up of 10.5 years (IQR, 0.1-29.3).Twenty-year transplant-free survival and freedom from HCM-related death were 80.6% (95% confidence interval [CI], 64.2%-100%) and 87.1% (95% CI, 71.8%-100%), respectively.The 20-year cumulative probability of HCM-related reintervention was 34.2% (95% CI, 12.8%-57.1%).Seven patients required a septal reintervention.There was no difference in any primary endpoints between patients with and without a RASopathy.Conclusions: Surgery for obstructive HCM, including septal myectomy with and without a modified Konno procedure, may be performed with low morbidity and good long-term outcomes in pediatric patients.Recurrent outflow tract obstruction is not uncommon.(JTCVS Open 2023;16:726-38) Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium characterized by pathologic ventricular septal thickening and left ventricular outflow tract (LVOT) obstruction.Histologic hallmarks include myocyte hypertrophy and disarray and interstitial fibrosis. 1Clinically, HCM is a heterogeneous disorder with variability in From the a Section of Pediatric and Congenital Cardiac Surgery and
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2023) conducted a cohort in obstructive hypertrophic cardiomyopathy (n=37). left and/or right ventricular septal myectomy was evaluated on transplantation-free survival (95% CI 64.2-100). Surgery for obstructive HCM in pediatric patients resulted in a 20-year transplant-free survival of 80.6% (95% CI, 64.2-100) and freedom from HCM-related death of 87.1%.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: